tetano
Editor, Senior Moderator
Cent Eur J Public Health
. 2024 Dec;32(Supplement):104-110.
doi: 10.21101/cejph.a8398. Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study
Ondrej Zahornacký[SUP] 1 [/SUP], Štefan Porubčin[SUP] 1 [/SUP], Alena Rovňáková[SUP] 1 [/SUP], Pavol Jarčuška[SUP] 1 [/SUP], Dária Semenovová[SUP] 1 [/SUP], Paulína Kubalcová[SUP] 2 [/SUP], Erik Dorko[SUP] 3 [/SUP], Kvetoslava Rimárová[SUP] 3 [/SUP]
Affiliations
Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.
Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.
Results: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020).
Conclusion: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.
Keywords: COVID-19; Slovakia; centre; molnupiravir; risk factors; single; study; treatment.
. 2024 Dec;32(Supplement):104-110.
doi: 10.21101/cejph.a8398. Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study
Ondrej Zahornacký[SUP] 1 [/SUP], Štefan Porubčin[SUP] 1 [/SUP], Alena Rovňáková[SUP] 1 [/SUP], Pavol Jarčuška[SUP] 1 [/SUP], Dária Semenovová[SUP] 1 [/SUP], Paulína Kubalcová[SUP] 2 [/SUP], Erik Dorko[SUP] 3 [/SUP], Kvetoslava Rimárová[SUP] 3 [/SUP]
Affiliations
- PMID: 39832155
- DOI: 10.21101/cejph.a8398
Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.
Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.
Results: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020).
Conclusion: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.
Keywords: COVID-19; Slovakia; centre; molnupiravir; risk factors; single; study; treatment.